My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

February 16, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Expert Ratings For Intra-Cellular Therapies ↗

February 16, 2022

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Analyst Ratings For Intra-Cellular Therapies ↗

December 20, 2021

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observe...

Via Benzinga

Intra-Cellular Therapies Inc.: The Winning Streak Continues ↗

February 16, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Intra-Cellular Therapies Inc. (NASDAQ:...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2022 ↗

February 16, 2022

Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49...

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 21, 2022

Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...

Via Benzinga

53 Biggest Movers From Friday ↗

January 24, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...

Via Benzinga

34 Stocks Moving In Friday's Mid-Day Session ↗

January 21, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....

Via Benzinga

45 Biggest Movers From Yesterday ↗

January 05, 2022

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 04, 2022

Gainers Hoth Therapeutics (NASDAQ:

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

January 04, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 04, 2022

Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 68.7% to $1.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $28....

Via Benzinga

23 Stocks Moving in Tuesday's Pre-Market Session ↗

January 04, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and corporate update. NeuroBo Pharmaceuticals, Inc...

Via Benzinga

IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med ↗

January 04, 2022

Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an...

Via Benzinga

A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report ↗

January 04, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year....

Via Benzinga

5 Stocks To Watch For January 4, 2022 ↗

January 04, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 03, 2022

Gainers Indaptus Therapeutics (NASDAQ:INDP

Via Benzinga

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression ↗

December 20, 2021

The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 20, 2021

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 20, 2021

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

Via InvestorPlace

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗

December 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

November 10, 2021

Benzinga Pro data, Intra-Cellular Therapies (NASDAQ:ITCI) reported Q3 sales of $22.21 million. Earnings fell to a loss of $77.32 million, resulting in a 11.83% decrease from last...

Via Benzinga

Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

ITCI earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Intra-Cellular Therapies: Q3 Earnings Insights ↗

November 09, 2021

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.